Difference between revisions of "Tepotinib (Tepmetko)"
m (Jwarner moved page Tepotinib (EMD-1214063) to Tepotinib (Tepmetko): FDA approval with new brand name) |
m |
||
| Line 11: | Line 11: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer, MET-mutated]] | *[[Non-small cell lung cancer, MET-mutated]] | ||
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 20:29, 3 February 2021
General information
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Diseases for which it is used
History of changes in FDA indication
- 2/3/2021: Granted accelerated approval for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Also known as
- Code names: EMD-1214063, MSC-2156119, MSC-2156119J
- Brand name: Tepmetko